The absence of MICB and ULBP-1 in baseline serum, signifying that MICB and ULBP-1 had reduced shedding, is significantly correlated with improved survival in patients with metastatic melanoma treated with immune checkpoint blockade [53]. The gene discussed is MICB; the disease is metastatic melanoma.